Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event will take place on September 26, 2024.
Amir Inamdar, Cybin's Chief Medical Officer, will be part of a panel discussion titled 'Advancement in Psychedelic Therapies for Neuropsychiatry'. The panel will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET.
Interested parties can access the webcast through a provided link. An archived version of the webcast will also be available on Cybin's investor relations website under the Events & Presentations page.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), un azienda innovativa nel campo della neuropsichiatria in fase clinica, ha annunciato la sua partecipazione al 4° Summit Annuale sulle Nuove Meccanismi in Neuropsichiatria di TD Cowen. L'evento virtuale si terrà il 26 settembre 2024.
Amir Inamdar, Chief Medical Officer di Cybin, sarà parte di una discussione panel intitolata 'Avanzamenti nelle Terapie Psichedeliche per la Neuropsichiatria'. Il panel sarà trasmesso in diretta giovedì, 26 settembre 2024, alle 10:00 a.m. ET.
Le parti interessate potranno accedere alla trasmissione attraverso un link fornito. Una versione archiviata della trasmissione sarà anche disponibile sul sito web delle relazioni con gli investitori di Cybin nella pagina Eventi e Presentazioni.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), una empresa innovadora en neuropsiquiatría en etapa clínica, ha anunciado su participación en el 4to Summit Anual sobre Nuevos Mecanismos en Neuropsiquiatría de TD Cowen. El evento virtual tendrá lugar el 26 de septiembre de 2024.
Amir Inamdar, Director Médico de Cybin, formará parte de una discusión en panel titulada 'Avances en Terapias Psicodélicas para Neuropsiquiatría'. El panel será transmitido en vivo el jueves, 26 de septiembre de 2024, a las 10:00 a.m. ET.
Las partes interesadas pueden acceder a la transmisión a través de un enlace proporcionado. Una versión archivada de la transmisión también estará disponible en el sitio web de relaciones con inversores de Cybin en la página de Eventos y Presentaciones.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN)은 임상 단계의 혁신적인 신경정신의학 회사로, TD Cowen 제4회 신경정신의학의 새로운 메커니즘 정상 회담에 참여한다고 발표했습니다. 이 가상 이벤트는 2024년 9월 26일에 진행될 예정입니다.
Amir Inamdar Cybin의 최고 의료 책임자가 '신경정신의학을 위한 환각 요법의 발전'이라는 제목의 패널 토론에 참여합니다. 이 패널은 2024년 9월 26일 목요일 오전 10시(ET)부터 생중계됩니다.
관심 있는 당사자는 제공된 링크를 통해 생중계에 접근할 수 있습니다. 또한 Cybin의 투자자 관계 웹사이트의 이벤트 및 프레젠테이션 페이지에서 생중계의 녹음본도 확인할 수 있습니다.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), une entreprise innovante en neuropsychiatrie au stade clinique, a annoncé sa participation au 4ème Sommet Annuel sur les Nouveaux Mécanismes en Neuropsychiatrie de TD Cowen. L'événement virtuel aura lieu le 26 septembre 2024.
Amir Inamdar, directeur médical de Cybin, participera à une discussion en panel intitulée 'Avancées dans les Thérapies Psychédéliques pour la Neuropsychiatrie'. Le panel sera diffusé en direct le jeudi 26 septembre 2024, à 10h00 ET.
Les parties intéressées peuvent accéder à la diffusion à l'aide d'un lien fourni. Une version archivée de la diffusion sera également disponible sur le site web des relations avec les investisseurs de Cybin, dans la section Événements et Présentations.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), ein klinisch fortschrittliches Durchbruchunternehmen in der Neuropsychiatrie, gab seine Teilnahme am 4. jährlichen Summit zu neuen Mechanismen in der Neuropsychiatrie von TD Cowen bekannt. Die virtuelle Veranstaltung findet am 26. September 2024 statt.
Amir Inamdar, der Chief Medical Officer von Cybin, wird Teil einer Podiumsdiskussion mit dem Titel 'Fortschritte in der psychedelischen Therapie für die Neuropsychiatrie' sein. Die Diskussion wird am Donnerstag, den 26. September 2024, um 10:00 Uhr ET live übertragen.
Interessierte Parteien können auf die Übertragung über einen bereitgestellten Link zugreifen. Eine archivierte Version der Übertragung wird auch auf der Website von Cybin für Investorenbeziehungen unter der Seite Veranstaltungen & Präsentationen verfügbar sein.
- None.
- None.
The panel discussion, titled “Advancement in Psychedelic Therapies for Neuropsychiatry,” will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924826591/en/
Investor & Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
Source: Cybin Inc.
FAQ
When is Cybin participating in the TD Cowen Neuropsychiatry Summit?
What is the topic of the panel discussion featuring Cybin's CMO at the summit?
How can investors access the webcast of Cybin's panel discussion?
What time is Cybin's panel discussion scheduled for on September 26, 2024?
Which stock exchanges is Cybin (CYBN) listed on?
